Aktienanalyse zu Myriad Genetics Inc (MYGN)MYGNMyriad Genetics Inc

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Myriad Genetics Inc is a good buy right now due to its recent price surge of 46.23% over the last five days, indicating strong momentum, and the positive news of selling its Prenatal Health business for $210 million, which is expected to enhance its financial position significantly. However, the company has a forward P/E ratio of 54.05, indicating high expectations for future earnings, and a risk of further losses as evidenced by a net income loss of $34.1 million in the last quarter.

14 analysts cover MYGN: 2 rate it Buy, 9 Hold and 3 Sell. The average price target is 7.38.